Airway diseases

State of the art session
Chairs: M. Humbert (Le Kremlin-Bicêtre, France), T. Geiser (Bern, Switzerland)
Aims: To evaluate the use of short-acting beta-2 agonist (SABA) monotherapy and oral corticosteroid (OCS) use in asthma; to describe concerns related to the use of inhaled corticosteroids (ICS) in COPD; and to determine the optimal inhalation device for patients with COPD.

Is there a problem with short-acting beta-2 agonist monotherapy in asthma? D. Price (Singapore, Singapore)
Is there a problem with oral corticosteroid use in asthma? G. Brusselle (Ghent, Belgium)
Is there a problem with inhaled corticosteroid use in COPD? J. Chalmers (Dundee (Angus), United Kingdom)
ERS Short Guideline: Inhaled corticosteroid withdrawal in COPD M. Miravitlles (Barcelona (CT), Spain)